Nuvation Bio (NUVB) Investor presentation summary

Strategic focus and leadership

• Concentrates on developing first- or best-in-class oncology medicines for large unmet needs.

• Led by an experienced biotech team, including the founder of Medivation.

• Maintains a strong pro forma cash balance of ~$534 million as of March 31, 2026, supporting profitability without additional funding.

IBTROZI (taletrectinib) highlights

• Approved for advanced ROS1+ NSCLC in the U.S., Japan, and China, with >600 new patient starts since U.S. launch.

• Demonstrates potentially best-in-class efficacy: 89–90% ORR, 50-month median DOR, and 46-month median PFS in TKI-naïve patients.

• Safety profile is favorable, with only 6.5% discontinuation due to TEAEs and minimal severe adverse events.

• U.S. net product revenue reached ~$43 million to date, with a theoretical maximum market opportunity of ~$4 billion.

• NCCN Guidelines now include taletrectinib as a preferred first-line therapy for ROS1+ NSCLC.

Market opportunity and competitive landscape

• ROS1+ NSCLC market estimated at 3,000 new U.S. cases annually, with IBTROZI's clinical profile shifting the opportunity from incidence to prevalence.

• IBTROZI outperforms other ROS1 TKIs in efficacy and tolerability, with lower dose modification and neurological AE rates.

• Precedent in ALK and EGFR markets suggests potential for significant market expansion and share capture.